Drugmaker Vivus Inc. (NASDAQ:VVUS) said 12 June Thursday it has filed a lawsuit against Actavis PLC and its affiliates in a New Jersey federal court over its bid with the U.S. Food and Drug Administration to sell a generic version of Vivus’ prescription weight-loss drug Qsymia. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is 0.19%. On last trading day company shares ended up $5.28. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is 3.49%.
Wall Street has been betting heavily against Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Arena is one of the most heavily shorted biotech stocks out there with the shorts holding a stunning 21 percent of Arena’s float. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 1.40% in last trading session and ended the day on $6.50. ARNA gross Margin is 93.70% and its return on assets is -8.10%.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is 0.15%.
MannKind Corporation (NASDAQ:MNKD) of Valencia is exploring multiple partnerships to take its inhalable insulin drug Afrezza to market as the company awaits FDA approval. Chief Operating Officer Hakan Edstrom told analysts at the Goldman Sachs annual health care conference in Palos Verdes on Thursday that the company is in negotiations with several potential partners, many of them already in the market with diabetes treatments. MannKind Corporation (NASDAQ:MNKD) shares moved up 7.55% in last trading session and was closed at $10.52, while trading in range of $9.95 – $10.53. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 102.31%.
Australian Federal Police cyber security experts have teamed up with the Walt Disney Company (NYSE:DIS) to create a new online safety program for primary schools. The Walt Disney Company (NYSE:DIS) ended the last trading day at $82.80. Company weekly volatility is calculated as 1.31% and price to cash ratio as 35.16.The Walt Disney Company (NYSE:DIS) showed a negative weekly performance of -2.14%.
Vivendi SA-ADR (OTCMKTS:VIVHY) on 15 may said net profit fell 19% to 431 million euros ($591 million) from EUR534 million in the same period last year, dragged down by an exceptional tax charge linked to the pending sale of its French phone unit SFR. On last trading day company shares ended up $25.94.
Leave a Reply